Posted by Michael Wonder on 01 Nov 2016
CADTH supports the use of Entyvio in Crohn's disease
31 October 2016 - Takeda's Entyvio clocks up another CADTH recommendation.
The CADTH Canadian Drug Expert Committee has recommended that vedolizumab be reimbursed for the treatment of adults with moderately to severely active Crohn’s disease.
Treatment with vedolizumab should be discontinued if a clinical response is not achieved prior to the administration of a fourth dose of vedolizumab.
Furthermore, the cost of treatment with vedolizumab should not exceed the drug plan cost of the least costly alternative biologic treatment option.
